NEW YORK (GenomeWeb) – Exiqon today reported a 10 percent increase year over year in its third quarter revenues.

For the three months ended Sept. 30, Exiqon's total revenues increased to DKK 38.4 million ($5.7 million) from DKK 34.8 million in the prior-year period.

In a statement, the Danish firm said that product sales increased 29 percent to DKK 24.7 million from DKK 19.1 million in 2014.

The firm's net income for the quarter was down to DKK 727,000, or DKK .02 per share, compared to a profit of DKK 1.7 million, or DKK .04 per share, in Q3 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.